The U.S. Food and Drug Administration approved Moderna's mFlusiva on Aug. 6, 2026, marking the first time an mRNA-based seasonal flu vaccine received authorization [1], [3].
This approval represents a shift in influenza prevention by applying the rapid-production capabilities of mRNA technology to a virus that evolves quickly. By moving away from traditional egg-based manufacturing, health providers may be able to better match vaccines to circulating strains.
The vaccine is specifically approved for people 50 and older [2]. This target demographic is often at a higher risk for severe complications from influenza, making the adaptable nature of the mRNA platform a critical tool for public health [1], [4].
Moderna developed mFlusiva using the same mRNA platform that powered its COVID-19 vaccinations [1], [4]. This technology allows for a faster production cycle, a significant advantage given that flu strains are typically selected only months before the peak of the winter season.
The FDA announcement came from its headquarters in Silver Spring, Maryland [1], [2]. While traditional flu shots have been the standard for decades, the introduction of mFlusiva introduces a new mechanism for triggering the body's immune response to the flu virus [3].
Officials said that the goal is to provide a more adaptable vaccine that can be updated more efficiently than previous methods [1], [4]. The approval follows a high-profile reversal by the agency, clearing the way for the first-ever mRNA flu shot to enter the U.S. market [1].
“The FDA approved Moderna's mFlusiva, marking the first time an mRNA-based seasonal flu vaccine received authorization.”
The approval of mFlusiva signals a broader transition in vaccine science, moving toward platforms that can be digitally sequenced and manufactured rapidly. For older adults, this could mean vaccines that are more precisely tailored to the current season's dominant strains, potentially increasing efficacy compared to traditional egg-based vaccines which can occasionally suffer from 'egg-adaptation' mutations.
